GLYCART biotechnology AG is a startup based in Switzerland, most recent round Acquired.
GLYCART biotechnology AG is a company headquartered in Switzerland. GLYCART biotechnology AG has been acquired.
GLYCART biotechnology AG was a Swiss biotechnology company that developed engineered antibody-based therapeutics (glyco-engineered antibodies) targeting unmet clinical needs such as cancer. The company was acquired by Roche in 2005 for CHF 230 million.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.